Overview
Using fluorescence is turning into one of the premier technologies for drug discovery. To tap the full potential of these new and exciting opportunities, many challenges still need to be addressed: How to increase the stability of cell lines expressing fluorescent proteins; how to increase drug screening by using better disease models utilizing FP’s in whole organisms; how to develop better tools to enhance the
high-throughput applications; and how to improve effectiveness while lowering costs. These are some of the major issues to be discussed at CHI's
Third Annual Fluorescent Proteins in Drug Development
conference. Join top experts and discuss your newest discoveries, technologies and case studies with a knowledgeable audience.
Sessions Include: Presenting Companies:
-
Novel Probes and Techniques
-
Assay Development
-
Real Time Imaging
-
Optical Imaging
- Bioluminescence
|
-
AntiCancer, Inc.
-
Los Alamos National Laboratory
-
Merck & Co., Inc.
-
National Institutes of Health
- Novartis Pharmaceuticals
Corporation
...and more!
|
|
For more information about this
conference, please contact:
Margit Eder, Ph.D., Conference Director, Cambridge Healthtech
Institute
Phone: 781-972-5478 – Fax: 781-972-5425 - E-mail: meder@healthtech.com
For sponsorship or exhibiting information, please contact:
Carol Dinerstein, Business Development Manager, Cambridge Healthtech
Institute
Phone: 781-972-5471
– Fax: 781-972-5425
– E-mail: dinerstein@healthtech.com
